David Kendall
Net worth: 836 257 $ as of 28/02/2026
Net worth: 836 257 $ as of 28/02/2026
David M.
Kendall currently works at Zealand Pharma A, as Chief Medical Officer from 2022.
Dr. Kendall also formerly worked at Amylin Pharmaceuticals, Inc., as Medical Director from 2005 to 2008, Park Nicollet Health Services, as Director & Medical Director from 1994 to 1997, International Diabetes Center, as Medical Director from 1997 to 2009, Eli Lilly & Co., as Vice President-Global Medical Affairs from 2011 to 2018, MannKind Corp., as Chief Medical Officer from 2018 to 2020, American Diabetes Association, as Chief Scientific & Medical Affairs Officer from 2009 to 2011, and Lilly Diabetes, as Vice President-Global Medical Affairs from 2011 to 2018.
Dr. Kendall received his undergraduate degree in 1983 from St. Olaf College and doctorate degree in 1988 from the University of Minnesota.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ZEALAND PHARMA A/S 0.02% | 31/12/2025 | 14,546 ( 0.02% ) | 836 257 $ | 28/02/2026 |
| Companies | Position | Start |
|---|---|---|
| ZEALAND PHARMA A/S | Chief Tech/Sci/R&D Officer | 02/06/2022 |
| Companies | Position | End |
|---|---|---|
| MANNKIND CORPORATION | Chief Tech/Sci/R&D Officer | 28/08/2020 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/02/2018 |
Lilly Diabetes | Corporate Officer/Principal | 01/01/2018 |
American Diabetes Association
American Diabetes Association Miscellaneous Commercial ServicesCommercial Services Provides diabetes related medical services | Chief Tech/Sci/R&D Officer | 01/07/2011 |
International Diabetes Center
International Diabetes Center Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit health care organization that provides diabetic treatment and research services | Chief Tech/Sci/R&D Officer | 01/09/2009 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 10 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Health Technology |
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
MannKind Corp.
MannKind Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes therapeutic products | Health Technology |
St. Olaf College
St. Olaf College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Minnesota
University of Minnesota Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zealand Pharma A/S
Zealand Pharma A/S BiotechnologyHealth Technology Operates as a biotechnology company that discovers and develops peptide based medicines | Health Technology |
American Diabetes Association
American Diabetes Association Miscellaneous Commercial ServicesCommercial Services Provides diabetes related medical services | Commercial Services |
Park Nicollet Health Services
Park Nicollet Health Services Hospital/Nursing ManagementHealth Services Provides healthcare services | Health Services |
International Diabetes Center
International Diabetes Center Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit health care organization that provides diabetic treatment and research services | Commercial Services |
Lilly Diabetes |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition